Covista Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CVSA research report →
Range $145 – $175
Price Chart
About the company
Covista Inc. is an enterprise dedicated to providing higher education. The company organizes its operations into three primary divisions: Chamberlain, Walden, and Medical and Veterinary.
- CEO
- Stephen W. Beard
- IPO
- 2026
- Employees
- 4,754
- HQ
- Chicago, IL, US
Get TickerSpark's AI analysis on CVSA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $3.63B
- P/E
- 13.83
- Fwd P/E
- 11.96
- PEG
- 0.71
- P/S
- 1.81
- P/B
- 2.61
- EV/EBITDA
- 8.71
- Div Yield
- 0.00%
- Gross Margin
- 57.39%
- Op Margin
- 19.86%
- Net Margin
- 12.84%
- ROE
- 18.33%
- ROIC
- 13.53%
Latest fiscal year · YoY change
- Revenue
- $1.95B+9.3%
- Gross Profit
- $1.12B+10.2%
- Op Income
- $383.38M
- Net Income
- $251.57M+8.1%
- EPS
- $7.63+21.7%
- OCF Growth
- +39.2%
- FCF Growth
- +36.6%
- 52W High
- $142.13
- 52W Low
- $86.97
- 50D MA
- $124.03
- 200D MA
- $120.01
- Beta
- 0.66
- RSI (14)
- 40
- Avg Volume
- 379.47K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Covista delivered a strong first quarter, beat on revenue and EPS, raised full-year guidance, and said its enrollment-led growth continues to support expansion, cash generation, and buybacks.· October 29, 2026
- Q1 revenue rose 10.7% to $511.5 million, adjusted EBITDA rose 17.1% to $131.2 million, and adjusted EPS rose 25.1% to $2.19.
- Total enrollment increased 7.6% to nearly 105,000 students, marking the 13th consecutive quarter of total enrollment growth.
- Management raised fiscal 27 guidance for both revenue and adjusted EPS, while still calling the outlook prudent for the remaining quarters.
- Capital allocation remained aggressive: the company repurchased $84 million of stock in the quarter and ended with net leverage of 0.5x.
- CEO Stephen Beard emphasized new campuses, employer partnerships, and AI-enabled technology as the main long-term growth levers.
First-quarter revenue increased 10.7% to $511.5 million. Adjusted EBITDA was $131.2 million, up 17.1% year over year, with adjusted EBITDA margin at 25.6%, up 1.4 percentage points. Adjusted net income rose 16.8% to $75.8 million and adjusted EPS was $2.19, up 25.1%; diluted shares averaged 34.6 million, down about 2.5 million year over year. Free cash flow over the trailing 12 months was $355 million, up 11.4%, while capital expenditures rose to $99 million from $56 million and cash and equivalents ended at $222 million. For fiscal 27, Covista now expects revenue of $2.06 billion to $2.095 billion and adjusted EPS of $9.00 to $9.20, both raised from prior ranges.
Stephen Beard framed the quarter as validation of the company’s “purpose at scale” strategy, saying Covista is ahead of its fiscal 27 plan and generating cash to fund growth initiatives. He highlighted durable demand in healthcare education, continued enrollment momentum, and expansion through new campuses, employer partnerships, and technology investments. His tone was confident but measured, repeatedly noting that the company is taking a prudent view of the rest of the year.
Robert Phelan said the operating model is converting enrollment growth into profit and cash, with trailing-12-month free cash flow of $355 million and net leverage at 0.5x. He noted interest expense fell to $9.9 million from $11.1 million after debt actions, and that the company repriced its $510 million term loan B to SOFR plus 2%. He also said the company returned $84 million to shareholders via buybacks, still has $578 million remaining on its repurchase authorization, and expects full-year EBITDA margin expansion of 0 to 0.5 percentage points along with higher capex and a higher tax rate in fiscal 27.
Analysts asked whether confusion around loan caps and the nursing classification changed enrollment; management said no, and said the main effects were in medical and veterinary education, where some students pulled forward enrollment and some families were still learning financing options. On Chamberlain, management said Q1 enrollment was lighter than expected because fewer continuing students returned and RN-to-BSN was soft, but they expect improvement through the year. Analysts also pressed on the modest guide raise versus the strong quarterly beat; management pointed to full-year guidance discipline, the Walden calendar shift, campus startup costs, and a higher tax rate as reasons to stay prudent.
The bull case from the call is that demand for healthcare education remains durable, enrollment is still growing across all three segments, and the business is converting that growth into higher margins, cash flow, and buybacks. Management also sounded confident that new campuses, health-system partnerships, and AI-driven technology can extend the company’s competitive position.
The main risks are that the full-year outlook stays cautious despite the strong quarter, Chamberlain’s enrollment growth was only 1.3% and still has weakness in continuing students and RN-to-BSN, and campus expansion is creating upfront costs before enrollment ramps. Management also flagged a second-quarter comparison hit from Walden’s calendar shift, plus higher capex and a higher tax rate for fiscal 27.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.3%
- Shares Outstanding
- 33.26M
- Float Shares
- 32.35M
Buy/sell ratio 1.11. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 417 ETFs
Biggest fund positions in CVSA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Phelan Robert J. | other | 624 |
| Nov 13, 26 | Liles Scott | other | 400 |
| Nov 13, 26 | Gangadharan Manjunath | other | 101 |
| Nov 13, 26 | BECK DOUGLAS G. | other | 362 |
| Nov 13, 26 | Betz Michael | other | 462 |
| Nov 13, 26 | Beard, Stephen W. | other | 9,205 |
| Nov 11, 26 | Betz Michael | other | 8,365 |
| Nov 12, 26 | Betz Michael | other | 838 |
| Nov 11, 26 | Betz Michael | other | 9,410 |
| Nov 11, 26 | Vandenbosch Betty M. | other | 1,255 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CVSA coverage
Recent articles, reports, and earnings notes.
No research on CVSA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CVSA report →Is Covista Inc. (CVSA) Stock Outpacing Its Consumer Discretionary Peers This Year?
zacks.com · Nov 20
Covista: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 16
Here's Why Covista (CVSA) is a Strong Value Stock
zacks.com · Nov 13
After Plunging 14.7% in 4 Weeks, Here's Why the Trend Might Reverse for Covista (CVSA)
zacks.com · Nov 9
Is Covista Inc. (CVSA) Outperforming Other Consumer Discretionary Stocks This Year?
zacks.com · Nov 4
Here's Why Covista (CVSA) is a Strong Growth Stock
zacks.com · Nov 3
Covista: Stronger Results Keep Me Bullish, But Cash Flow Needs To Improve
seekingalpha.com · Oct 30
Covista (CVSA) Beats Q1 Earnings and Revenue Estimates
zacks.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.